204 related articles for article (PubMed ID: 28833566)
1. High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus.
Wenzel J; Landmann A; Vorwerk G; Kuhn A
Exp Dermatol; 2018 Jan; 27(1):95-97. PubMed ID: 28833566
[TBL] [Abstract][Full Text] [Related]
2. B lymphocyte stimulator modulates number and function of endothelial progenitor cells in systemic lupus erythematosus.
Spinelli FR; Barbati C; Cecarelli F; Morello F; Colasanti T; Vomero M; Massaro L; Orefice V; Alessandri C; Valesini G; Conti F
Arthritis Res Ther; 2019 Nov; 21(1):245. PubMed ID: 31752963
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic signal molecules in skin biopsies of cutaneous lupus erythematosus: analysis using tissue microarray.
Toberer F; Sykora J; Göttel D; Hartschuh W; Werchau S; Enk A; Joos S; Krammer PH; Kuhn A
Exp Dermatol; 2013 Oct; 22(10):656-9. PubMed ID: 24079735
[TBL] [Abstract][Full Text] [Related]
4. B Cell Signatures Distinguish Cutaneous Lupus Erythematosus Subtypes and the Presence of Systemic Disease Activity.
Abernathy-Close L; Lazar S; Stannard J; Tsoi LC; Eddy S; Rizvi SM; Yee CM; Myers EM; Namas R; Lowe L; Reed TJ; Wen F; Gudjonsson JE; Kahlenberg JM; Berthier CC
Front Immunol; 2021; 12():775353. PubMed ID: 34868043
[TBL] [Abstract][Full Text] [Related]
5. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.
Fetter T; Smith P; Guel T; Braegelmann C; Bieber T; Wenzel J
Front Immunol; 2020; 11():344. PubMed ID: 32194562
[TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory Endogenous Nucleic Acids Drive the Lesional Inflammation in Cutaneous Lupus Erythematosus.
Scholtissek B; Zahn S; Maier J; Klaeschen S; Braegelmann C; Hoelzel M; Bieber T; Barchet W; Wenzel J
J Invest Dermatol; 2017 Jul; 137(7):1484-1492. PubMed ID: 28351661
[TBL] [Abstract][Full Text] [Related]
7. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.
Wenzel J; Wörenkämper E; Freutel S; Henze S; Haller O; Bieber T; Tüting T
J Pathol; 2005 Mar; 205(4):435-42. PubMed ID: 15685590
[TBL] [Abstract][Full Text] [Related]
8. The role of B lymphocyte stimulator in B cell biology: implications for the treatment of lupus.
Scholz JL; Oropallo MA; Sindhava V; Goenka R; Cancro MP
Lupus; 2013 Apr; 22(4):350-60. PubMed ID: 23553778
[TBL] [Abstract][Full Text] [Related]
9. The deposition of anti-DNA IgG contributes to the development of cutaneous lupus erythematosus.
Dong Y; Zhang Y; Xia L; Wang P; Chen J; Xu M; Liu X; Xia Y
Immunol Lett; 2017 Nov; 191():1-9. PubMed ID: 28899632
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases as mediators of tissue injury in different forms of cutaneous lupus erythematosus.
Järvinen TM; Kanninen P; Jeskanen L; Koskenmies S; Panelius J; Hasan T; Ranki A; Saarialho-Kere U
Br J Dermatol; 2007 Nov; 157(5):970-80. PubMed ID: 17854363
[TBL] [Abstract][Full Text] [Related]
11. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
12. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients.
Braegelmann C; Hölzel M; Ludbrook V; Dickson M; Turan N; Ferring-Schmitt S; Sternberg S; Bieber T; Kuhn A; Wenzel J
Exp Dermatol; 2016 May; 25(5):375-9. PubMed ID: 26910509
[TBL] [Abstract][Full Text] [Related]
13. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
14. Tissue microarray analysis of RANKL in cutaneous lupus erythematosus and psoriasis.
Toberer F; Sykora J; Göttel D; Ruland V; Hartschuh W; Enk A; Luger TA; Beissert S; Loser K; Joos S; Krammer PH; Kuhn A
Exp Dermatol; 2011 Jul; 20(7):600-2. PubMed ID: 21692859
[TBL] [Abstract][Full Text] [Related]
15. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of guanylate binding protein-1 in lesional skin of patients with cutaneous lupus erythematosus.
Naschberger E; Wenzel J; Kretz CC; Herrmann M; Stürzl M; Kuhn A
Exp Dermatol; 2011 Feb; 20(2):102-6. PubMed ID: 21121962
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous lupus erythematosus: The impact of self-amplifying innate and adaptive immune responses and future prospects of targeted therapies.
Fetter T; Wenzel J
Exp Dermatol; 2020 Nov; 29(11):1123-1132. PubMed ID: 32633821
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus.
Popovic K; Ek M; Espinosa A; Padyukov L; Harris HE; Wahren-Herlenius M; Nyberg F
Arthritis Rheum; 2005 Nov; 52(11):3639-45. PubMed ID: 16255056
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema.
Zhang YP; Wu J; Han YF; Shi ZR; Wang L
Autoimmun Rev; 2017 Jul; 16(7):735-742. PubMed ID: 28483542
[TBL] [Abstract][Full Text] [Related]
20. Role of the chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus.
Wenzel J; Henze S; Wörenkämper E; Basner-Tschakarjan E; Sokolowska-Wojdylo M; Steitz J; Bieber T; Tüting T
J Invest Dermatol; 2005 Jun; 124(6):1241-8. PubMed ID: 15955100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
